Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

Fabio Efficace, Gianantonio Rosti, Francesco Cottone, Massimo Breccia, Fausto Castagnetti, Alessandra Iurlo, Franco Mandelli, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

The main objective of this study was to outline key characteristics, including health-related quality of life (HRQOL) and symptoms, in 175 chronic myeloid leukemia (CML) patients reporting intentional or unintentional reasons for not fully adhering to imatinib therapy. There was a significant higher proportion of males in the unintentional group (P= 0.037). Also, in this group patients were on average younger (P= 0.046). Patients reporting intentional reasons had generally a worse HRQOL profile and a higher symptom severity than those who reported unintentional reasons for non-adherence. This study suggests that patients with suboptimal adherence are not a homogenous group, thus generalized approaches to improve medication-taking behaviors are not recommended.

Original languageEnglish
Pages (from-to)294-298
Number of pages5
JournalLeukemia Research
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Quality of Life
Therapeutics

Keywords

  • Adherence to therapy
  • Chronic myeloid leukemia
  • Quality of life
  • Symptoms

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. / Efficace, Fabio; Rosti, Gianantonio; Cottone, Francesco; Breccia, Massimo; Castagnetti, Fausto; Iurlo, Alessandra; Mandelli, Franco; Baccarani, Michele.

In: Leukemia Research, Vol. 38, No. 3, 03.2014, p. 294-298.

Research output: Contribution to journalArticle

Efficace, Fabio ; Rosti, Gianantonio ; Cottone, Francesco ; Breccia, Massimo ; Castagnetti, Fausto ; Iurlo, Alessandra ; Mandelli, Franco ; Baccarani, Michele. / Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. In: Leukemia Research. 2014 ; Vol. 38, No. 3. pp. 294-298.
@article{cc0764a2a5f547c6b6f321d80cd577fa,
title = "Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors",
abstract = "The main objective of this study was to outline key characteristics, including health-related quality of life (HRQOL) and symptoms, in 175 chronic myeloid leukemia (CML) patients reporting intentional or unintentional reasons for not fully adhering to imatinib therapy. There was a significant higher proportion of males in the unintentional group (P= 0.037). Also, in this group patients were on average younger (P= 0.046). Patients reporting intentional reasons had generally a worse HRQOL profile and a higher symptom severity than those who reported unintentional reasons for non-adherence. This study suggests that patients with suboptimal adherence are not a homogenous group, thus generalized approaches to improve medication-taking behaviors are not recommended.",
keywords = "Adherence to therapy, Chronic myeloid leukemia, Quality of life, Symptoms",
author = "Fabio Efficace and Gianantonio Rosti and Francesco Cottone and Massimo Breccia and Fausto Castagnetti and Alessandra Iurlo and Franco Mandelli and Michele Baccarani",
year = "2014",
month = "3",
doi = "10.1016/j.leukres.2013.07.003",
language = "English",
volume = "38",
pages = "294--298",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

AU - Efficace, Fabio

AU - Rosti, Gianantonio

AU - Cottone, Francesco

AU - Breccia, Massimo

AU - Castagnetti, Fausto

AU - Iurlo, Alessandra

AU - Mandelli, Franco

AU - Baccarani, Michele

PY - 2014/3

Y1 - 2014/3

N2 - The main objective of this study was to outline key characteristics, including health-related quality of life (HRQOL) and symptoms, in 175 chronic myeloid leukemia (CML) patients reporting intentional or unintentional reasons for not fully adhering to imatinib therapy. There was a significant higher proportion of males in the unintentional group (P= 0.037). Also, in this group patients were on average younger (P= 0.046). Patients reporting intentional reasons had generally a worse HRQOL profile and a higher symptom severity than those who reported unintentional reasons for non-adherence. This study suggests that patients with suboptimal adherence are not a homogenous group, thus generalized approaches to improve medication-taking behaviors are not recommended.

AB - The main objective of this study was to outline key characteristics, including health-related quality of life (HRQOL) and symptoms, in 175 chronic myeloid leukemia (CML) patients reporting intentional or unintentional reasons for not fully adhering to imatinib therapy. There was a significant higher proportion of males in the unintentional group (P= 0.037). Also, in this group patients were on average younger (P= 0.046). Patients reporting intentional reasons had generally a worse HRQOL profile and a higher symptom severity than those who reported unintentional reasons for non-adherence. This study suggests that patients with suboptimal adherence are not a homogenous group, thus generalized approaches to improve medication-taking behaviors are not recommended.

KW - Adherence to therapy

KW - Chronic myeloid leukemia

KW - Quality of life

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=84894276295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894276295&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.07.003

DO - 10.1016/j.leukres.2013.07.003

M3 - Article

C2 - 23906625

AN - SCOPUS:84894276295

VL - 38

SP - 294

EP - 298

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -